Literature DB >> 15271954

N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.

Karin Baraldo1, Elena Mori, Antonella Bartoloni, Roberto Petracca, Aldo Giannozzi, Francesco Norelli, Rino Rappuoli, Guido Grandi, Giuseppe Del Giudice.   

Abstract

N19, a string of human universal CD4 T-cell epitopes from various pathogen-derived antigens, was shown to exert a stronger carrier effect than CRM197 for the induction of anti-group C Neisseria meningitidis capsular polysaccharide (MenC), after immunization of mice with various dosages of N19-MenC or CRM-MenC conjugate vaccines. After two immunizations, the N19-based construct induced anti-MenC antibody and protective bactericidal antibody titers higher than those induced by three doses of the CRM-MenC conjugate and required lower amounts of conjugate. N19-based conjugates are superior to CRM-based conjugates to induce protective immune responses to MenC conjugates.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15271954      PMCID： PMC470654          DOI： 10.1128/IAI.72.8.4884-4887.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

Review 1.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

Review 2.  New carriers and adjuvants in the development of vaccines.

Authors:  G Del Giudice
Journal:  Curr Opin Immunol       Date:  1992-08       Impact factor: 7.486

3.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

4.  Use of prior vaccinations for the development of new vaccines.

Authors:  H M Etlinger; D Gillessen; H W Lahm; H Matile; H J Schönfeld; A Trzeciak
Journal:  Science       Date:  1990-07-27       Impact factor: 47.728

5.  Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming.

Authors:  C Barrios; A R Lussow; J Van Embden; R Van der Zee; R Rappuoli; P Costantino; J A Louis; P H Lambert; G Del Giudice
Journal:  Eur J Immunol       Date:  1992-06       Impact factor: 5.532

6.  Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.

Authors:  A Fattom; Y H Cho; C Chu; S Fuller; L Fries; R Naso
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

7.  Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination.

Authors:  D Valmori; A Pessi; E Bianchi; G Corradin
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

8.  Effect of infant immunisation with meningococcus serogroup C-CRM(197) conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children.

Authors:  Jodie McVernon; Jenny MacLennan; Elizabeth Clutterbuck; Jim Buttery; E Richard Moxon
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

9.  Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay.

Authors:  G M Carlone; C E Frasch; G R Siber; S Quataert; L L Gheesling; S H Turner; B D Plikaytis; L O Helsel; W E DeWitt; W F Bibb
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses.

Authors:  D M Granoff; S E Maslanka; G M Carlone; B D Plikaytis; G F Santos; A Mokatrin; H V Raff
Journal:  Clin Diagn Lab Immunol       Date:  1998-07
View more
  11 in total

1.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella.

Authors:  Renee M Laird; Zuchao Ma; Nelum Dorabawila; Brittany Pequegnat; Eman Omari; Yang Liu; Alexander C Maue; Steven T Poole; Milton Maciel; Kavyashree Satish; Christina L Gariepy; Nina M Schumack; Annette L McVeigh; Frédéric Poly; Cheryl P Ewing; Michael G Prouty; Mario A Monteiro; Stephen J Savarino; Patricia Guerry
Journal:  Vaccine       Date:  2018-09-27       Impact factor: 3.641

3.  Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis.

Authors:  Varinder Kumar; N k Ganguly; Kusum Joshi; Rahul Mittal; Kusum Harjai; Sanjay Chhibber; Saroj Sharma
Journal:  Med Microbiol Immunol       Date:  2005-05-21       Impact factor: 3.402

4.  Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.

Authors:  Isamu Tsuji; Shuji Sato; Kentaro Otake; Takahiro Watanabe; Hiroko Kamada; Tomofumi Kurokawa
Journal:  MAbs       Date:  2012-09-24       Impact factor: 5.857

5.  Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.

Authors:  Anahit Ghochikyan; Hayk Davtyan; Irina Petrushina; Armine Hovakimyan; Nina Movsesyan; Arpine Davtyan; Anatoly Kiyatkin; David H Cribbs; Michael G Agadjanyan
Journal:  Hum Vaccin Immunother       Date:  2013-02-11       Impact factor: 3.452

6.  Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques.

Authors:  Claire F Evans; Hayk Davtyan; Irina Petrushina; Armine Hovakimyan; Arpine Davtyan; Drew Hannaman; David H Cribbs; Michael G Agadjanyan; Anahit Ghochikyan
Journal:  Alzheimers Dement       Date:  2013-07-31       Impact factor: 21.566

7.  Combination vaccines.

Authors:  David Ag Skibinski; Barbara C Baudner; Manmohan Singh; Derek T O'Hagan
Journal:  J Glob Infect Dis       Date:  2011-01

Review 8.  Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.

Authors:  Francesca Micoli; Roberto Adamo; Paolo Costantino
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

9.  Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21.

Authors:  Amritha Ramakrishnan; Nina M Schumack; Christina L Gariepy; Heather Eggleston; Gladys Nunez; Nereyda Espinoza; Monica Nieto; Rosa Castillo; Jesus Rojas; Andrea J McCoy; Zoltan Beck; Gary R Matyas; Carl R Alving; Patricia Guerry; Frédéric Poly; Renee M Laird
Journal:  mSphere       Date:  2019-05-01       Impact factor: 4.389

10.  A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice.

Authors:  Yun-Zhou Yu; Si Liu; Hai-Chao Wang; Dan-Yang Shi; Qing Xu; Xiao-Wei Zhou; Zhi-Wei Sun; Pei-Tang Huang
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.